engleski

Recommendations for reporting results of quantitave PCR bcr-abl1 in purpose of monitoring minimal residual disease and scoring depth of molecular response in CML patients on therapy

Najnovije preporuke za praćenje minimalne ostatne bolesti i procjene dubine molekularnog odgovora u bolesnika koji boluju od kronične mijeloične leukemije i na terapiji su tirozin kinaznim inhibitorima

bcr-abl1 quantitative PCR; monitoring minimal residual disease; scoring deep molecular response

nije evidentirano